Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
Journal of Clinical Oncology2009Vol. 27(34), pp. 5743–5750
Citations Over TimeTop 1% of 2009 papers
Michael Weller, Jörg Felsberg, Christian Hartmann, Hilmar Berger, Joachim P. Steinbach, Johannes Schramm, Manfred Westphal, Gabriele Schackert, Matthias Simon, Jörg C. Tonn, Oliver Heese, Dietmar Krex, Guido Nikkhah, Torsten Pietsch, Otmar D. Wiestler, Guido Reifenberger, Andreas von Deimling, Markus Loeffler
Abstract
Molecular changes associated with gliomagenesis do not predict response to therapy in glioblastoma patients managed according to current standards of care. MGMT promoter methylation and IDH1 mutational status allow for stratification into prognostically distinct subgroups.
Related Papers
- → Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report(2021)4 cited
- → [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].(2018)1 cited
- [Feature analysis of IDH1 mutation in oligodendroglial tumors].(2012)
- Isocitrate dehydrogenase 1 mutations and human gliomas(2011)
- → Multiple gliomas(2022)